NAYA Biosciences Corp (NAYA) - יתרות מזומנים למניה

NAYA Biosciences delegates drug production and testing to external contractors to maintain team mobility. The cash per share forecast demonstrates liquidity dynamics, where the value 1.40 captures this metric. NAYA Biosciences is developing unique multispecific antibodies to combat cancer, leveraging a powerful scientific foundation. Independence from the global economy transforms such developments into a resilient defensive asset.
פילוחי מדדים מקיפים ואנליטיקה עבור NAYA Biosciences Inc (NAYA)

Developing bispecific antibodies to combat solid tumors requires significant R&D capital expenditures for NAYA Biosciences (NAYA). This metric is calculated by dividing the total volume of liquid assets by the number of shares outstanding. By analyzing the current cash per share, an investor determines the intrinsic value of the security and its financial cushion. A stable indicator minimizes the risk of default during prolonged clinical trials, serving as a key solvency indicator for a biopharmaceutical startup.